{"id":16844,"date":"2022-04-01T17:44:45","date_gmt":"2022-04-01T12:14:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16844"},"modified":"2022-05-19T10:48:49","modified_gmt":"2022-05-19T05:18:49","slug":"treatment-resistant-hypertension-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market","title":{"rendered":"Treatment-resistant Hypertension: Insights into the Challenges and Solutions"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a448a9156f20\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a448a9156f20\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market\/#Treatment-resistant_Hypertension_Epidemiology_Insights\" >Treatment-resistant Hypertension Epidemiology Insights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market\/#Treatment-resistant_Hypertension_Market_Scenario\" >Treatment-resistant Hypertension Market Scenario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market\/#Market_Leaders_in_the_Making\" >Market Leaders in the Making<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market\/#Expected_Roadblocks\" >Expected Roadblocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market\/#Way_Ahead\" >Way Ahead<\/a><\/li><\/ul><\/nav><\/div>\n\n<p id=\"h-\">Resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of <strong>\u22653<\/strong> antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin-angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.<\/p>\n\n\n\n<p>Secondary causes of Resistant Hypertension include Obstructive Sleep Apnea, Renal Artery Stenosis, Renal Parenchymal Disease, and Primary Aldosteronism, along with some uncommon Resistant Hypertension causes such as Pheochromocytoma, Cushing&#8217;s disease, thyroid, and parathyroid dysfunction, and aortic coarctation.<\/p>\n\n\n\n<p>Resistant Hypertension Symptoms may appear when blood pressure first begins to rise or during a hypertensive crisis when levels are incredibly high. Headaches, shortness of breath, chest pain, and nosebleeds are some of the Resistant Hypertension symptoms. To confirm persistently elevated blood pressure levels, the Resistant Hypertension diagnosis necessitates using a good blood pressure technique. Pseudoresistance, including lack of blood pressure control due to poor medication adherence or white coat hypertension, must be ruled out.<\/p>\n\n\n\n<p>The pathophysiology of Hypertension can be attributed to aldosterone excess in more than <strong>20%<\/strong> of patients with resistant hypertension. Existing dogma attributes the increase in blood pressure seen with increases in aldosterone to its antinatriuretic effects in the distal nephron. However, emerging research has identified and begun to define the function of amiloride-sensitive sodium channels and mineralocorticoid receptors in the systemic vasculature; challenges impaired natriuresis as the sole cause of aldosterone-mediated resistant hypertension.<\/p>\n\n\n\n<p>The treatment for Resistant Hypertension is focused on the addition of fourth-line therapy where blood pressure is not controlled by treatment with three drugs, described by NICE as A + C + D: that is, an ACE inhibitor or an angiotensin II receptor blocker (A), a calcium channel antagonist (C), and a thiazide or thiazide-like diuretic (D). The most recommended drug therapy for Resistant Hypertension as a fourth-line agent is spironolactone in patients with potassium of <strong>&lt;4.5 mmol\/L<\/strong> who are likely to respond to a mineralocorticoid receptor blocker. For patients with potassium of <strong>&gt;4.5 mmol\/L<\/strong>, it is recommended that the existing diuretic (thiazide or thiazide-like) be doubled.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-resistant-hypertension-epidemiology-insights\"><span class=\"ez-toc-section\" id=\"Treatment-resistant_Hypertension_Epidemiology_Insights\"><\/span><strong>Treatment-resistant Hypertension Epidemiology Insights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The 7MM <a href=\"https:\/\/www.delveinsight.com\/report-store\/resistant-hypertension-epidemiology-forecast\">Treatment-resistant Hypertension prevalent cases<\/a> were over <strong>16 million <\/strong>in 2021. The United States accounted for the highest number of Treatment-resistant Hypertension cases, followed by EU5 countries and Japan. Japan had <strong>approx 2 million cases<\/strong> of Treatment-resistant Hypertension in 2021, while the EU5 countries together accounted for nearly <strong>4.5 million cases<\/strong>, <strong>as per DelveInsight\u2019s assessments.<\/strong><\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-8ba527b9-50bd-40ed-96c0-6da6e5129eb9\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"429\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 520 429\" width=\"520\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.0.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-tiwidrn-789-\"><rect fill=\"none\" height=\"343\" width=\"500\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-tiwidrn-791-\"><rect fill=\"none\" height=\"343\" width=\"500\" x=\"10\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"429\" rx=\"0\" ry=\"0\" width=\"520\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"343\" width=\"500\" x=\"10\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"343\" width=\"500\" x=\"10\" y=\"71\"><\/rect><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" aria-label=\"\" class=\"highcharts-series highcharts-series-0 highcharts-pyramid-series\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(10,71) scale(1 1)\"><path aria-label=\"1. 7MM, 16. Numbers in Million.\" class=\"highcharts-point highcharts-color-0\" d=\"M 25 343 L 475 343 L 364.2307692307692 174.13846153846154 L 135.76923076923077 174.13846153846154 Z\" fill=\"#7cb5ec\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"2. US, 10. Numbers in Million.\" class=\"highcharts-point highcharts-color-1\" d=\"M 135.76923076923077 174.13846153846154 L 364.2307692307692 174.13846153846154 L 295 68.60000000000002 L 205 68.60000000000002 Z\" fill=\"#434348\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"3. EU5, 4.5. Numbers in Million.\" class=\"highcharts-point highcharts-color-2\" d=\"M 205 68.59999999999997 L 295 68.59999999999997 L 263.8461538461538 21.107692307692275 L 236.1538461538462 21.107692307692275 Z\" fill=\"#90ed7d\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"4. Japan, 2. Numbers in Million.\" class=\"highcharts-point highcharts-color-3\" d=\"M 236.15384615384613 21.107692307692332 L 263.84615384615387 21.107692307692332 L 250 0 L 250 0 Z\" fill=\"#f7a35c\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-pyramid-series\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(10,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"260\" y=\"24\">Epidemiology Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"260\" y=\"52\">Source: Treatment-resistant Hypertension Epidemiology Forecast 2032<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"426\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-pyramid-series\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(10,71) scale(1 1)\"><path class=\"highcharts-data-label-connector highcharts-color-0\" d=\"M 449.61538461538464 258.5692307692308 C 444.61538461538464 258.5692307692308 429.61538461538464 258.5692307692308 424.61538461538464 258.5692307692308 L 419.61538461538464 258.5692307692308\" fill=\"none\" stroke=\"#7cb5ec\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-1\" d=\"M 359.61538461538464 121.3692307692308 C 354.61538461538464 121.3692307692308 339.61538461538464 121.36923076923078 334.61538461538464 121.36923076923078 L 329.61538461538464 121.36923076923078\" fill=\"none\" stroke=\"#434348\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-2\" d=\"M 309.4230769230769 44.85384615384612 C 304.4230769230769 44.85384615384612 289.4230769230769 44.85384615384612 284.4230769230769 44.85384615384612 L 279.4230769230769 44.85384615384612\" fill=\"none\" stroke=\"#90ed7d\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-3\" d=\"M 286.9230769230769 10.553846153846166 C 281.9230769230769 10.553846153846166 266.9230769230769 10.553846153846166 261.9230769230769 10.553846153846166 L 256.9230769230769 10.553846153846166\" fill=\"none\" stroke=\"#f7a35c\" stroke-width=\"1\"><\/path><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(455,249)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">7MM<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>7MM<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(365,111)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">US<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>US<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-2\" data-z-index=\"1\" transform=\"translate(314,35)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">EU5<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>EU5<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-3\" data-z-index=\"1\" transform=\"translate(292,1)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Japan<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Japan<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-legend highcharts-no-tooltip\" data-z-index=\"7\"><rect class=\"highcharts-legend-box\" fill=\"none\" height=\"8\" rx=\"0\" ry=\"0\" visibility=\"hidden\" width=\"8\" x=\"0\" y=\"0\"><\/rect><g data-z-index=\"1\"><g><\/g><\/g><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Treatment-resistant Hypertension Epidemiology Forecast 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"510\" y=\"424\">Treatment-resistant Hypertension Epidemiology Forecast 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-tiwidrn-791-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Epidemiology Insights\"},\"subtitle\":{\"text\":\"Source: Treatment-resistant Hypertension Epidemiology Forecast 2032\"},\"exporting\":{},\"chart\":{\"type\":\"pyramid\",\"width\":520,\"height\":429},\"plotOptions\":{\"series\":{\"datalabels\":{\"color\":\"#000000\"},\"dataLabels\":{\"softConnector\":true},\"animation\":false}},\"series[0]\":{\"width\":\"64%\"},\"series\":[{\"name\":\"Numbers in Million\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Numbers in Million\\\"\\n\\\"7MM\\\";16\\n\\\"US\\\";10\\n\\\"EU5\\\";4.5\\n\\\"Japan\\\";2\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{}}],\"credits\":{\"text\":\"Treatment-resistant Hypertension Epidemiology Forecast 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/resistant-hypertension-epidemiology-forecast\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-8ba527b9-50bd-40ed-96c0-6da6e5129eb9\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>Moreover, among the European countries, <strong>Germany<\/strong> had the highest number of prevalent cases of treatment-resistant hypertension (<strong>&gt;1.4 million<\/strong>) in 2021.<strong> <\/strong>At the same time, the <strong>UK<\/strong> had the lowest number of prevalent cases (~<strong>600k<\/strong>)<strong> <\/strong>in 2021, which as per DelveInsight\u2019s estimates, are expected to reach <strong>around 640,000 <\/strong>cases by 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Treatment-resistant_Hypertension_Market_Scenario\"><\/span><strong>Treatment-resistant Hypertension Market Scenario<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The main strategies adopted for treatment-resistant hypertension include nonpharmacological and pharmacological interventions. Nonpharmacological interventions include <strong>lifestyle modifications, a DASH diet, reduced salt intake, restricted alcohol consumption,<\/strong> etc. Pharmacological interventions include withdrawal of interfering Resistance Hypertension medications, optimization of diuretic therapy, mineralocorticoids, combination therapy, and the use of <strong>spironolactone as the fourth agent for treating Resistant Hypertension.&nbsp;<\/strong><\/p>\n\n\n\n<p>Disease associations and other organized programs for <a href=\"https:\/\/www.delveinsight.com\/report-store\/resistant-hypertension-epidemiology-forecast\">Treatment-resistant Hypertension patients<\/a> are established in most regions. Some prominent ones include <strong>the American Society of Hypertension (ASH), World Hypertension League, Pan American Health Organization (PAHO), International Society of Hypertension (ISH)<\/strong>. These organizations provide opportunities to map Treatment-resistant Hypertension patients and improve their access to innovative Resistant Hypertension treatment and outcomes. Soon, establishing country-wide registries in cooperation with these centers may also help tackle the disease further.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-6595bb25-5944-4789-acd8-f6dcf7a2d5be\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.0.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-wq2rk5f-325-\"><rect fill=\"none\" height=\"293\" width=\"489\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-wq2rk5f-327-\"><rect fill=\"none\" height=\"293\" width=\"489\" x=\"10\" y=\"92\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"293\" width=\"489\" x=\"10\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"293\" width=\"489\" x=\"10\" y=\"92\"><\/rect><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" aria-label=\"\" class=\"highcharts-series highcharts-series-0 highcharts-pie-series\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(10,92) scale(1 1)\"><path aria-label=\"1. 7MM, 13,000. Numbers in Million.\" class=\"highcharts-point highcharts-color-0\" d=\"M 244.47545737895473 42.00000249933716 A 120.5 120.5 0 1 1 213.6145355585835 278.97462421591234 L 244.5 162.5 A 0 0 0 1 0 244.5 162.5 Z\" fill=\"#7cb5ec\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"2. US, 9,200. Numbers in Million.\" class=\"highcharts-point highcharts-color-1\" d=\"M 213.49807639651098 278.9436805193113 A 120.5 120.5 0 0 1 189.4562041214961 55.306574197455575 L 244.5 162.5 A 0 0 0 0 0 244.5 162.5 Z\" fill=\"#434348\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"3. Germany, 860. Numbers in Million.\" class=\"highcharts-point highcharts-color-2\" d=\"M 189.56342505132875 55.251584007459456 A 120.5 120.5 0 0 1 214.75916742217353 45.727859154772304 L 244.5 162.5 A 0 0 0 0 0 244.5 162.5 Z\" fill=\"#90ed7d\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"4. Italy, 600. Numbers in Million.\" class=\"highcharts-point highcharts-color-3\" d=\"M 214.87595441397184 45.698176713216824 A 120.5 120.5 0 0 1 233.38295895905884 42.51391164599943 L 244.5 162.5 A 0 0 0 0 0 244.5 162.5 Z\" fill=\"#f7a35c\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><path aria-label=\"5. UK, 350. Numbers in Million.\" class=\"highcharts-point highcharts-color-4\" d=\"M 233.50295058593525 42.50285459985051 A 120.5 120.5 0 0 1 244.33262791746236 42.000116238288484 L 244.5 162.5 A 0 0 0 0 0 244.5 162.5 Z\" fill=\"#8085e9\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-linejoin=\"round\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(0,0)\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-pie-series\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(10,92) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Treatment-resistant Hypertension Market<tspan dy=\"21\" x=\"255\">\u200b<\/tspan>Landscape<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"73\">Source: Treatment-resistant Hypertension Market Insights - 2032<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-pie-series\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(10,92) scale(1 1)\"><path class=\"highcharts-data-label-connector highcharts-color-0\" d=\"M 398.7263368763489 182.03843347012307 C 393.7263368763489 182.03843347012307 375.8786686785132 179.7016108624007 369.92944594590125 178.92266999315993 L 363.9802232132893 178.14372912391914\" fill=\"none\" stroke=\"#7cb5ec\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-1\" d=\"M 89.85492013859349 178.5187413136383 C 94.85492013859349 178.5187413136383 112.7526705539112 176.60287856516328 118.7185873590171 175.96425764900494 L 124.68450416412301 175.3256367328466\" fill=\"none\" stroke=\"#434348\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-2\" d=\"M 129.30018148835273 60 C 134.30018148835273 60 197.68323417614818 38.54661990169603 199.80323866628487 44.15960315143055 L 201.92324315642156 49.77258640116507\" fill=\"none\" stroke=\"#90ed7d\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-3\" d=\"M 157.96473155744195 36 C 162.96473155744195 36 222.0704460224745 31.91223216407569 223.0861239384379 37.82564051891 L 224.10180185440132 43.73904887374431\" fill=\"none\" stroke=\"#f7a35c\" stroke-width=\"1\"><\/path><path class=\"highcharts-data-label-connector highcharts-color-4\" d=\"M 232.6101392928957 12 C 237.6101392928957 12 238.4341757894265 30.13891895029559 238.7088546216034 36.132628280848245 L 238.9835334537803 42.1263376114009\" fill=\"none\" stroke=\"#8085e9\" stroke-width=\"1\"><\/path><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(404,172)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">7MM<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>7MM<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(60,169)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">US<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>US<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-2\" data-z-index=\"1\" transform=\"translate(65,50)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Germany<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Germany<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-3\" data-z-index=\"1\" transform=\"translate(119,26)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">Italy<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>Italy<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-4\" data-z-index=\"1\" transform=\"translate(200,2)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">UK<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>UK<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-legend highcharts-no-tooltip\" data-z-index=\"7\"><rect class=\"highcharts-legend-box\" fill=\"none\" height=\"8\" rx=\"0\" ry=\"0\" visibility=\"hidden\" width=\"8\" x=\"0\" y=\"0\"><\/rect><g data-z-index=\"1\"><g><\/g><\/g><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Treatment-resistant Hypertension Market Insights - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Treatment-resistant Hypertension Market Insights - 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-wq2rk5f-327-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Treatment-resistant Hypertension Market Landscape\"},\"subtitle\":{\"text\":\"Source: Treatment-resistant Hypertension Market Insights - 2032\"},\"exporting\":{},\"chart\":{\"type\":\"pie\"},\"series\":[{\"name\":\"Numbers in Million\",\"turboThreshold\":0}],\"plotOptions\":{\"series\":{\"animation\":false}},\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Numbers in Million\\\"\\n\\\"7MM\\\";13000\\n\\\"US \\\";9200\\n\\\"Germany\\\";860\\n\\\"Italy\\\";600\\n\\\"UK\\\";350\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{}}],\"credits\":{\"text\":\"Treatment-resistant Hypertension Market Insights - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-hypertension-market\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-6595bb25-5944-4789-acd8-f6dcf7a2d5be\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>According to the first comprehensive global analysis of <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-epidemiology-forecast\">trends in Hypertension prevalence<\/a>, detection, treatment, and control, led by Imperial College London and WHO, the number of adults aged 30\u201379 with hypertension has increased from <strong>650 million<\/strong> to <strong>1.28 billion<\/strong> in the last 30 years. Low awareness rate, moderate treatment rate, and high levels of nonadherence result in an increased incidence of uncontrolled hypertension in diagnosed and treated <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-pipeline-insight\">Hypertension patients<\/a>.<\/p>\n\n\n\n<p>Treatment-resistant Hypertension (RHTN) is known to be associated with higher rates of major adverse <a href=\"https:\/\/www.delveinsight.com\/blog\/digital-therapeutics\">cardiovascular diseases events<\/a> and increased mortality relative to nonresistant hypertension. The patients with Treatment-resistant Hypertension were older, heavier, less likely to have a high income, and differed in additional ways from the much larger group with non-resistant Hypertension. A multivariate analysis found that RHTN was associated with <strong>USD 2,413<\/strong> in excess annual medical expenditures and <strong>USD 1,253<\/strong> in excess total prescription expenditures, for a total of <strong>USD 3,647<\/strong> excess total annual healthcare expenditures per person, compared with subjects with non-resistant Hypertension.<\/p>\n\n\n\n<p>According to DelveInsight, the lion\u2019s share of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-hypertension-market\">Treatment-resistant Hypertension market<\/a> remains with the United States throughout the forecast period (2019\u20132032). The Treatment-resistant Hypertension market size in the US was <strong>USD 9,298.5 million<\/strong> in 2019 and is likely to reach <strong>USD 15 billion<\/strong> by 2032.<\/p>\n\n\n\n<p>In 2019, among EU5, <strong>Germany <\/strong>accounted for the largest Resistant Hypertension market size (~<strong>USD<\/strong> <strong>860 million<\/strong>), followed by <strong>Italy<\/strong> with <strong>(approx. USD 600 million)<\/strong>,<strong> <\/strong>whereas the <strong>UK <\/strong>accounted for the smallest market size (~<strong>USD 350 million<\/strong>).<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160439\/Key-Companies-in-the-Treatment-resistant-Hypertension-Market.png\" alt=\"Key Companies in the Treatment-resistant Hypertension Market\" class=\"wp-image-16847\" width=\"792\" height=\"264\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160439\/Key-Companies-in-the-Treatment-resistant-Hypertension-Market.png 792w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160439\/Key-Companies-in-the-Treatment-resistant-Hypertension-Market-300x100.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160439\/Key-Companies-in-the-Treatment-resistant-Hypertension-Market-150x50.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160439\/Key-Companies-in-the-Treatment-resistant-Hypertension-Market-768x256.png 768w\" sizes=\"(max-width: 792px) 100vw, 792px\" \/><figcaption><strong>Major Pharma &amp; Biotech Giants in the Treatment-resistant Hypertension Market<\/strong><\/figcaption><\/figure>\n\n\n\n<p>The future of the Treatment-resistant Hypertension market looks promising with emerging therapies such as<strong> are firibastat (Quantum Genomics), aprocitentan (Idorsia Pharmaceuticals), CIN-107 (CinCor Pharma), IONIS-AGT-LRx (Ionis Pharmaceuticals), <\/strong>and<strong> patiromer (Vifor Pharma), <\/strong>among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Market_Leaders_in_the_Making\"><\/span><strong>Market Leaders in the Making<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With a few promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/resistant-hypertension-pipeline-insight\">drugs for Resistant Hypertension in the pipeline<\/a>, the Treatment-resistant Hypertension market size is projected to grow. Among the emerging therapies, the most promising ones include<strong> firibastat (Quantum Genomics) \u2013 a Phase III Glutamyl aminopeptidase inhibitors, aprocitentan (Idorsia Pharmaceutical) \u2013 a Phase III endothelin receptor antagonists<\/strong>, and <strong>CIN-107 \u2013 Phase II aldosterone synthase inhibitor (ASI)<\/strong>, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Expected_Roadblocks\"><\/span><strong>Expected Roadblocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Lifestyle factors such as excessive alcohol and salt intake contribute to the presence of Resistant Hypertension. Large amounts of alcohol consumption (three or more drinks per day) have an important dose-related effect on BP levels in both normotensive and hypertensive patients. Usually, patients with Resistant Hypertension present an average sodium intake that exceeds <strong>10 g\/day.<\/strong> Salt not only increases BP levels but also blunts the antihypertensive effect of the BP-lowering drugs. These effects are much more pronounced in salt-sensitive patients (elders, African-Americans, and patients with chronic kidney disease).<\/p>\n\n\n\n<p>Moreover, <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-causes-diagnosis-risk-factors-treatment-market\">Obesity and increased body mass index<\/a> significantly increase BP levels. The mechanisms that induce hypertension in those patients include activating the sympathetic nervous system and renin-angiotensin-aldosterone system and insulin resistance, and impaired sodium excretion. The adoption of current European Society of Cardiology\/European Society of Hypertension guidelines on lifestyle changes may significantly decrease BP levels in those patients and contribute to BP control.<\/p>\n\n\n\n<p>Finally, several drugs and substances may increase BP levels. <strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)<\/strong> probably represent the most common agents in worsening BP control. The use of NSAIDs increases BP levels and can blunt the effect of various antihypertensive drugs such as <strong>diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers<\/strong>. The hypertensive effect of NSAIDs is more pronounced in patients with chronic kidney disease. Other substances that can increase BP levels are decongestants and stimulant agents used for weight loss and also contraceptives, cyclosporine, erythropoietin, and cortisone that increase BP levels mainly through fluid retention.<\/p>\n\n\n\n<p>Obstructive Sleep Apnea, Primary Aldosteronism, and Chronic Kidney Disease represent the most common secondary causes of Resistant Hypertension, whereas several other conditions may also be responsible for treatment resistance. Despite differences in definitions, a consistent body of evidence supports the concept that RHTN is associated with an increased risk of adverse long\u2013term cardiovascular and kidney outcomes. In a clinical study, <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-ckd-pipeline-insight\">participants with CKD<\/a> and apparent RHTN had a <strong>38%<\/strong> higher risk of cardiovascular events or all-cause mortality, a <strong>28%<\/strong> higher risk of ESRD, or a<strong> 50%<\/strong> decline in GFR (Braam et al., 2017). The diagnostic workup for secondary hypertension is demanding, requires special knowledge and technology, and should be performed in specialized referral centers familiar with secondary hypertension.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The incidence and prevalence of Resistant Hypertension remain unclear as there are no direct studies to evaluate this. Extrapolation of data from large-scale antihypertensive trials suggests <strong>10\u201320% prevalence<\/strong>. The exact prevalence of Resistant Hypertension in the general population remains unknown. According to the studied populations, data from small observational studies show a wide variation (from <strong>5% to 50%<\/strong>). Data from large clinical trials (designed population studies) point toward a relatively high prevalence of Resistant Hypertension (<strong>20\u201335%<\/strong>). Therefore, evaluating the prevalence of resistant hypertension requires a large, prospective, population-based study specially designed for this aim.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s estimates, the Treatment-resistant Hypertension market landscape looks promising, studded with remarkable advances in diagnosis and treatments that will translate into a better quality of life and improved survival. The entry of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/resistant-hypertension-pipeline-insight\">novel therapies for Resistant Hypertension<\/a> to attain better healthcare will necessitate collaboration among academia, life-sciences companies, funding, regulatory agencies, decision-makers, and caregivers. In addition, expertise in navigating market access and reimbursement scenarios would be an elixir to devise successful GTM strategies for new therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-hypertension-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market-1024x256.png\" alt=\"Treatment-resistant Hypertension Market\" class=\"wp-image-16848\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01160547\/Treatment-resistant-Hypertension-Market.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>FAQs<\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1648808316916\"><strong class=\"schema-faq-question\">1. What is Resistant Hypertension?<\/strong> <p class=\"schema-faq-answer\">Resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of \u22653 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin-angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1648808332062\"><strong class=\"schema-faq-question\"><strong>2. What are the symptoms of Resistant Hypertension?<\/strong><\/strong> <p class=\"schema-faq-answer\">Resistant Hypertension Symptoms may appear when blood pressure first begins to rise or when levels are extremely high during a hypertensive crisis. Headaches, shortness of breath, chest pain, and nosebleeds are some of the Resistant Hypertension symptoms.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1648808339004\"><strong class=\"schema-faq-question\">3. Which are the leading companies in the Treatment-resistant Hypertension market?<\/strong> <p class=\"schema-faq-answer\">The leading players in the Treatment-resistant Hypertension market include Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, among others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1648808350811\"><strong class=\"schema-faq-question\">4. Which are the emerging therapies in the Treatment-resistant Hypertension market?<\/strong> <p class=\"schema-faq-answer\">The most promising therapies in the Treatment-resistant Hypertension pipeline include firibastat (Quantum Genomics) \u2013 a Phase III Glutamyl aminopeptidase inhibitors, aprocitentan (Idorsia Pharmaceutical) \u2013 a Phase III endothelin receptor antagonists, and CIN-107 \u2013 Phase II aldosterone synthase inhibitor (ASI).<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of \u22653 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin-angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses. Secondary [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":16861,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[4044,19214,19211,19213,19212],"industry":[17225],"therapeutic_areas":[17242],"class_list":["post-16844","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-hypertension","tag-resistant-hypertension","tag-treatment-resistant-hypertension","tag-treatment-resistant-hypertension-epidemiology","tag-treatment-resistant-hypertension-market","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>What are the Challenges in Treatment-resistant Hypertension Market?<\/title>\n<meta name=\"description\" content=\"Treatment-resistant Hypertension (RHTN) is known to be associated with higher rates of major adverse cardiovascular diseases events.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What are the Challenges in Treatment-resistant Hypertension Market?\" \/>\n<meta property=\"og:description\" content=\"Treatment-resistant Hypertension (RHTN) is known to be associated with higher rates of major adverse cardiovascular diseases events.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-01T12:14:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-19T05:18:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/02122644\/Treatment-resistant-Hypertension-Market-Analysis-and-Emerging-Therapies.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"What are the Challenges in Treatment-resistant Hypertension Market?","description":"Treatment-resistant Hypertension (RHTN) is known to be associated with higher rates of major adverse cardiovascular diseases events.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market","og_locale":"en_US","og_type":"article","og_title":"What are the Challenges in Treatment-resistant Hypertension Market?","og_description":"Treatment-resistant Hypertension (RHTN) is known to be associated with higher rates of major adverse cardiovascular diseases events.","og_url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-04-01T12:14:45+00:00","article_modified_time":"2022-05-19T05:18:49+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/02122644\/Treatment-resistant-Hypertension-Market-Analysis-and-Emerging-Therapies.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market","url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market","name":"What are the Challenges in Treatment-resistant Hypertension Market?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/02122644\/Treatment-resistant-Hypertension-Market-Analysis-and-Emerging-Therapies.png","datePublished":"2022-04-01T12:14:45+00:00","dateModified":"2022-05-19T05:18:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Treatment-resistant Hypertension (RHTN) is known to be associated with higher rates of major adverse cardiovascular diseases events.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808316916"},{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808332062"},{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808339004"},{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808350811"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/02122644\/Treatment-resistant-Hypertension-Market-Analysis-and-Emerging-Therapies.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/02122644\/Treatment-resistant-Hypertension-Market-Analysis-and-Emerging-Therapies.png","width":772,"height":482,"caption":"Treatment-resistant Hypertension Market Analysis and Emerging Therapies"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808316916","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808316916","name":"1. What is Resistant Hypertension?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of \u22653 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin-angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808332062","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808332062","name":"2. What are the symptoms of Resistant Hypertension?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Resistant Hypertension Symptoms may appear when blood pressure first begins to rise or when levels are extremely high during a hypertensive crisis. Headaches, shortness of breath, chest pain, and nosebleeds are some of the Resistant Hypertension symptoms.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808339004","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808339004","name":"3. Which are the leading companies in the Treatment-resistant Hypertension market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The leading players in the Treatment-resistant Hypertension market include Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, among others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808350811","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-hypertension-market#faq-question-1648808350811","name":"4. Which are the emerging therapies in the Treatment-resistant Hypertension market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The most promising therapies in the Treatment-resistant Hypertension pipeline include firibastat (Quantum Genomics) \u2013 a Phase III Glutamyl aminopeptidase inhibitors, aprocitentan (Idorsia Pharmaceutical) \u2013 a Phase III endothelin receptor antagonists, and CIN-107 \u2013 Phase II aldosterone synthase inhibitor (ASI).","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/02122644\/Treatment-resistant-Hypertension-Market-Analysis-and-Emerging-Therapies-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Resistant Hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Treatment-resistant Hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Treatment-resistant Hypertension Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Treatment-resistant Hypertension Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">hypertension<\/span>","<span class=\"advgb-post-tax-term\">Resistant Hypertension<\/span>","<span class=\"advgb-post-tax-term\">Treatment-resistant Hypertension<\/span>","<span class=\"advgb-post-tax-term\">Treatment-resistant Hypertension Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Treatment-resistant Hypertension Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Apr 1, 2022","modified":"Updated on May 19, 2022"},"absolute_dates_time":{"created":"Posted on Apr 1, 2022 5:44 pm","modified":"Updated on May 19, 2022 10:48 am"},"featured_img_caption":"Treatment-resistant Hypertension Market Analysis and Emerging Therapies","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16844"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16844\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16861"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16844"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16844"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}